Key Players
Competitive Landscape
Four supplier models compete in the HER2 therapy market: originator antibody franchise owners, antibody-drug conjugate co-development groups, biosimilar partnerships and bispecific or regional platform companies. Their commercial positions differ by approved biomarker group, tumor coverage and territory rights rather than company scale alone.
Capital and portfolio investment has moved in two directions since 2025, toward monetizing royalties from approved assets and funding lower-cost biologic entry. Zymeworks completed a USD 250 million royalty-backed note financing in March 2026, secured by 30% of future Ziihera royalties. Shanghai Henlius Biotech and Organon received the first US pertuzumab biosimilar approval in November 2025. Price remains relevant, but oncology systems sort suppliers first on approved-setting breadth, biomarker fit and treatment-delivery support.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Zymeworks entered a USD 250 million royalty-backed note financing tied to Ziihera royalties in March 2026. | Biotechnology licensors need capital without surrendering most future royalties and milestone payments from approved oncology assets. | Approved HER2 medicines are supporting royalty-backed financing rather than equity issuance alone. | Additional Ziihera indications can generate milestones and royalties across biliary tract and gastroesophageal cancer. |
| RemeGen received Chinese approval for disitamab vedotin in HER2-low metastatic breast cancer with liver metastases in March 2026. | Oncologists need options for HER2-low disease with liver metastases and limited choices following systemic therapy. | Regional ADC developers are extending labels into narrower biomarker and metastatic subgroups. | Chinese sales and regional licensing can expand across approved HER2-expressing tumor indications. |
| Shanghai Henlius Biotech and Organon received FDA approval for POHERDY as the first US pertuzumab biosimilar in November 2025. | Oncology systems seek lower-cost access to established dual-HER2 regimens across early and metastatic breast cancer. | Biosimilar competition is moving beyond trastuzumab into additional components of established combination treatment. | Hospital contracting and formulary conversion can generate revenue across approved reference-product indications. |
Roche Holding AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Pfizer Inc., Merck & Co., Inc., Amgen Inc., Jazz Pharmaceuticals plc and BeOne Medicines Ltd. also compete through indication breadth, combination regimens, biosimilars or regional commercialization without a separate capital event mapped in this three-row table.
Source: Future Market Insights, HER2 Therapy Market and Companion Diagnostics Market Reports, 2026-2036, linked official company and regulator records.
The reviewed companies collectively cover originator antibodies, ADCs, kinase combinations, biosimilar entry, bispecific licensing and region-specific commercialization across major HER2 treatment pathways.
Who leads the HER2 therapy market?
Roche has the broadest established originator-antibody coverage among the reviewed companies, supported by trastuzumab and pertuzumab platforms across early and metastatic breast cancer. AstraZeneca and Daiichi Sankyo compete through trastuzumab deruxtecan, which extends ADC coverage across breast and several non-breast settings.
Which suppliers have documented regulatory approvals across HER2 settings?
Roche reports approved trastuzumab and pertuzumab regimens, while AstraZeneca and Daiichi Sankyo hold trastuzumab deruxtecan approvals across several settings. Jazz holds Ziihera authorization in biliary tract cancer and a first-line gastroesophageal filing under priority review. Henlius and Organon obtained interchangeable pertuzumab biosimilar approval, while RemeGen holds four Chinese disitamab vedotin indications.
Which companies provide breast cancer and non-breast HER2 therapies?
AstraZeneca and Daiichi Sankyo provide trastuzumab deruxtecan across breast, lung, gastric and tumor-agnostic solid-tumor pathways. Roche serves breast and gastric care, while Jazz covers biliary tract cancer and RemeGen supplies approved gastric, urothelial and breast cancer indications in China. Merck participates through a pembrolizumab combination in HER2-positive gastric or gastroesophageal junction cancer.
Which suppliers serve North America and Asia?
Daiichi Sankyo and AstraZeneca serve North America and Asia through global trastuzumab deruxtecan commercialization. Jazz holds Ziihera rights outside most of Asia, while BeOne Medicines serves Asia excluding India and Japan plus Australia and New Zealand. Henlius and Organon cover US and European pertuzumab biosimilar markets.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Roche Holding AG | Global | Herceptin, Perjeta, Kadcyla and Phesgo across breast cancer settings, ten-year APHINITY results reported in May 2025. |
| AstraZeneca PLC | Global | Co-develops Enhertu with Daiichi Sankyo; FDA approvals in May 2026 added neoadjuvant and adjuvant HER2-positive early breast cancer indications. |
| Daiichi Sankyo Company, Limited | Global with direct Japan commercialization | Co-develops and commercializes trastuzumab deruxtecan across breast and several solid-tumor settings with Daiichi Sankyo. |
| Pfizer Inc. | Global | Ibrance combined with trastuzumab, with or without pertuzumab, and endocrine therapy received FDA maintenance-treatment approval in June 2026. |
| Merck & Co., Inc. | Global | Discovered trastuzumab deruxtecan and received Japan tumor-agnostic HER2-positive solid-tumor approval in March 2026. |
| Amgen Inc. | Global biosimilar portfolio | KANJINTI remained an FDA-approved trastuzumab biosimilar for all Herceptin indications, supporting breast and gastric HER2 access through Amgen’s biosimilar portfolio. |
| Jazz Pharmaceuticals plc | Americas, Europe, Japan and other licensed territories | Palbociclib with trastuzumab and endocrine therapy received FDA maintenance-treatment approval in June 2026. |
| Zymeworks Inc. | Global licensing and royalty position | Ziihera royalty rights supported a USD 250 million royalty-backed financing in March 2026, retaining exposure to HER2-positive gastric and biliary tract cancer royalties. |
| BeOne Medicines Ltd. | Asia excluding India and Japan, Australia and New Zealand | Pembrolizumab with trastuzumab and chemotherapy holds FDA approval for first-line PD-L1-positive HER2-positive gastric or GEJ cancer. |
| Shanghai Henlius Biotech, Inc. and Organon & Co. | United States and Europe | POHERDY became the first FDA-approved interchangeable pertuzumab biosimilar in November 2025 for all Perjeta reference-product indications. |
| RemeGen Co., Ltd. | China with international development activity | KANJINTI remained within Amgen’s disclosed biosimilar portfolio in its full-year 2025 results. |
Research Methodology
The reviewed companies illustrate HER2 market structure and do not form a ranking of corporate size or overall oncology revenue. Each company appears only where current evidence confirms a HER2-directed medicine, approved combination, biosimilar or licensed platform in relevant treatment settings. Evidence comes from regulators, company filings, official releases, licensing records and current corporate disclosures covering January 2025 onward. Approvals are assigned to the medicine holder and jurisdiction named by each source, not automatically to the wider corporate group. The 42.0% monoclonal antibody share is an FMI estimate for 2026 and does not represent a company market share.
